The FDA’s emerging framework represents more than a regulatory update; it is a paradigm shift toward human-relevant, ...
Compared to Sotyktu (deucravacitinib), which was approved by the FDA for plaque psoriasis in 2022 and brought in sales of ...
Distilling that complexity into a handful of trends has been no small task. What follows is not a definitive forecast, but ...
Q4 2025 showcased the industry’s pivot toward precise biology, localised delivery, and earlier intervention – with multiple ...
The Coalition for Epidemic Preparedness Innovations (CEPI), a public-private partnership, is providing up to $54.3 million in ...
The green light for Rybrevant Faspro – which combines amivantamab with hyaluronidase – means that the drug is the first ...
Regulators in the UK and US are the first to approve GSK's Exdensur, a long-acting, twice-yearly IL-5 inhibitor for severe ...
Daiichi Sankyo and AstraZeneca have pressed swiftly to file for approval of their TROP2-targeting drug Datroway for ...
BMS signed a multiyear agreement with antibody specialist Harbour BioMed, which has operations in the US, the Netherlands, ...
In a new pharmaphorum podcast, web editor Nicole Raleigh speaks with Dr Amy Bucher, chief behavioural officer at Lirio, a ...
Dermot Kenny, who leads STEM and Research Partnership within Inizio Advisory, shares his journey from bench scientist to CEO, ...
At Frontiers Health 2025, the conversation around global brand launches was evolving rapidly – and EVERSANA and its agency ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback